The cost of managing diabetic foot ulceration in an Irish hospital

Irish Journal of Medical Science

Volumn 173, Issue 2, 2004, Pages 89-92

  Smith, D ^a   Cullen, M J ^a   Nolan, John J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; CLINDAMYCIN; FLUCLOXACILLIN; INSULIN; LEVOFLOXACIN; METFORMIN; METICILLIN; METRONIDAZOLE; ORAL ANTIDIABETIC AGENT; PENICILLIN G; RIFAMPICIN; SULFONYLUREA;

ADULT; AGED; BUDGET; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC FOOT; FEMALE; FOOT AMPUTATION; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH ECONOMICS; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; IRELAND; LENGTH OF STAY; MALE; MEDICAL AUDIT; MEDICAL RECORD; REVIEW; ULCER HEALING;

EID: 7244231218     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02914564     Document Type: Review

References (17)

1. Walters DP, Gatling W, Mullee MA, Hill RD. The distribution and severity of diabetic foot disease: a community based study with comparison to a non-diabetic group. Diabetic Medicine 1992; 9: 354-8.
2. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998; 176: 5S-10S.
3. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. The Lancet 2003; 361: 1545-51.
4. Apelqvist J, Agardh CD. The association between clinical risk factors and outcome of diabetic foot ulcers. Diabetes Res Clin Prac 1992; 18: 43-45.
5. Lithner FG. The diabetic foot: epidemiology and economic impact. IDF Bulletin 1992; 38: 7-9.
6. Reiber GE. Diabetic foot care. Financial implications and practice guidelines. Diabetes Care 1992; 15 Suppl (1): 29-31.
7. Jonsson B. Diabetes: the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand 1983; 671: 19-27.
8. VanAcker K, Oleen-Buckley M, DeDecker L et al. Cost and resource utilization for prevention and treatment of foot lesions in a diabetic foot clinic in Belgium. Diabetes Res Clin Pract 2000; 50: 87-95.
9. Tennvall GR, Apelqvist J, Eneroth M. Costs of deep foot infections in patients with diabetes mellitus. Pharmacoeconomics 2000; 18: 225-38.
10. Harding K, Cutting K, Price P. The cost-effectiveness of wound management protocols of care. Brit J Nurs 2000; 19: S6-S24.
11. Reiber GE, Vileikyte L, Boyko EJ et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-62.
12. Macfarlane RM, Jeffcoate WJ. Factors contributing to the presentation of diabetic foot ulcers. Diabetic Medicine 1997; 14: 867-70.
13. Delamaire M, Maugendre D, Moreno M et al. Impaired leucocyte function in diabetic patients. Diabetic Medicine 1997; 14: 29-34.
14. Adler EI, Boyko EJ, Ahroni JH et al. Lower-extremity amputation in diabetes: the independent effects of peripheral vascular disease, sensory neuropathy and foot ulcers. Diabetes Care 1999; 22: 1029-35.
15. Apelqvist J, Larsson J, Agardh C-D. Long term prognosis for diabetic patients with foot ulcers. J Intern Med 1993; 233: 485-91.
16. Ragnarsson T, Tennvall G, Apelqvist J. Prevention of diabetes-related foot ulcers and amputations: a cost utility analysis based on Markov model simulations. Diabetologia 2001; 44: 2077-81.
17. Horswell RL, Birke JA, Patout CA Jr. A staged management diabetes foot program versus standard care: a 1-year cost and utilization comparison in a state public hospital system. Arch Phys Med Rehab 2003; 84: 1743-46.